3-phenoxy-5-[(E)-2-piperidin-3-ylethenyl]pyridine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-phenoxy-5-[(E)-2-piperidin-3-ylethenyl]pyridine
• 化学式: C₁₈H₂₀N₂O
• 分子量: 280.4
• InChiKey: ZRXFOIONJMADTB-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Arylvinylazacycloalkane compounds and methods of preparation and use thereof
  申请人：Aventis Pharma S.A.

  公开号：US20040176348A1

  公开（公告）日：2004-09-09

  Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.

  公开了化合物的分子式为(I)的新型乙烯基氮杂环戊烷类化合物。这些化合物是各种nAChR的配体。这些化合物及其药学上可接受的盐可用于制备用于预防或治疗与nAChR功能紊乱相关的疾病的药物组合物和/或药物，特别是在中枢神经系统或胃肠系统内。可治疗的疾病类型的示例包括神经退行性疾病，包括中枢神经系统疾病，如阿尔茨海默病，认知障碍，帕金森病等运动障碍，药物成瘾，行为障碍以及胃肠系统内的炎症性疾病。这些化合物还可以作为镇痛剂用于治疗急性、慢性或复发性疼痛。
• ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
  申请人：Schmitt Jeffrey Daniel

  公开号：US20100010042A1

  公开（公告）日：2010-01-14

  Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.

  公开了式(I)的新型乙烯基氮杂环烷化合物，这些化合物是各种nAChRs的配体。这些化合物及其药学上可接受的盐可用于制备预防或治疗与nAChRs功能障碍相关的疾病的药物组合物和/或药物，特别是中枢神经系统或胃肠系统内的疾病。可以治疗的疾病类型的例子包括神经退行性疾病，包括中枢神经系统疾病，如阿尔茨海默病、认知障碍、运动障碍，如帕金森病、药物成瘾、行为障碍和胃肠系统内的炎症性疾病。这些化合物还可以作为镇痛剂用于治疗急性、慢性或反复发作的疼痛。
• Arylvinylazacycloalkane Compounds and Methods of Preparation and Use Thereof
  申请人：Schmitt Jeffrey Daniel

  公开号：US20080293778A1

  公开（公告）日：2008-11-27

  Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.

  本发明公开了一种化合物，其为式(I)的新型乙烯基氮杂环烷化合物。这些化合物是各种nAChRs的配体。这些化合物及其药学上可接受的盐可用于制备预防或治疗与nAChRs功能失调相关的紊乱的药物组合物和/或药物品。特别是在中枢神经系统或胃肠系统内的紊乱。可治疗的紊乱类型包括神经退行性疾病，包括中枢神经系统疾病，如阿尔茨海默病、认知障碍、运动障碍，如帕金森病、药物成瘾、行为障碍和胃肠系统内的炎症性疾病。这些化合物还可以作为镇痛剂用于治疗急性、慢性或反复发作的疼痛。
• JP2006519868A
  申请人：——

  公开号：JP2006519868A

  公开（公告）日：2006-08-31
• アリールビニルアザシクロアルカン化合物およびその調製方法ならびにその使用
  申请人：ターガセプト,インコーポレイテッド

  公开号：JP4663627B2

  公开（公告）日：2006-08-31